Trial Profile
A Phase I/IIa study evaluating anti-CD19 CAR T-cell therapy after low-dose chemotherapy in people with advanced lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2016
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 03 Nov 2016 According to a Kite Pharma media release, data from this study will be presented at 2016 American Society Hematology Annual Meeting
- 14 Jun 2016 New trial record
- 08 Jun 2016 Data from this trial will be presented at the 2016 European Hematology Association (EHA) Annual Congress, according to a Kite Pharma media release.